Market Overview

UPDATE: Deutsche Bank Reiterates Hold Rating, Raises PT on Forest Laboratories

Related FRX
Icahn's (Potential) Move Into Biotech
Carl Icahn's Track Record In Big Pharma

In a report published Wednesday, Deutsche Bank reiterated its Hold rating on Forest Laboratories (NYSE: FRX), and raised its price target from $34.00 to $36.00.

Deutsche Bank noted, “FRX reported Q3 non-GAAP loss per share of $0.21, $0.10 wider than consensus, with lower than expected revs (-$40M vs consensus) somewhat offset by a $31M tax benefit and slightly lower than projected operating expenses (-$5M).FRX again posted weak product revs of $678M (DBe $731M), with 3 of the 5 new launches (Bystolic, Daliresp, Viibryd) modestly below our ests. Also of note, flagship drug Namenda came in significantly below forecast at $346M (consensus was $384M), reflecting the impact of higher contract rebates driven by the Medicare Part D gap liability.”

Forest Laboratories closed on Tuesday at $37.85.

Latest Ratings for FRX

May 2014UBSMaintainsNeutral
Apr 2014Cantor FitzgeraldMaintainsHold
Apr 2014SunTrust Robinson HumphreyDowngradesBuyNeutral

View More Analyst Ratings for FRX
View the Latest Analyst Ratings

Posted-In: Deutsche BankAnalyst Color Price Target Analyst Ratings


Related Articles (FRX)

View Comments and Join the Discussion!

Partner Center